Navigation Links
Preclinical Update - Debio-0512 Therapeutic Vaccine for the,Treatment of Chronic and Acute Inflammatory Conditions

Proof of Concept in Mice Transgenic for Human TNFa

LAUSANNE, Switzerland, March 12, 2007 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions, announces the presentation of preclinical results that validate the mechanism of action of Debio-0512 as an anti-TNFa therapeutic vaccine, that inhibits inflammatory processes in animal models of acute and chronic inflammation. Debio-0512 is a keyhole limpet hemocyanin (KLH)-human TNFa heterocomplex (hTNFa kinoid). The results of this study, published recently in the Proceedings of the National Academy of Sciences (PNAS), were presented on March 10 at the 4th International Conference on Tumor Microenvironment in Florence, Italy.

"These results confirm that therapeutic vaccination against human TNFa could represent in the future, an effective approach for the treatment of TNFa-dependent inflammatory pathologies including rheumatoid arthritis and Crohn's disease," said Professor Daniel Zagury of the University Pierre et Marie Curie (Paris) and co-author of the report. "Debiopharm's plan is for IND enabling clinical studies to be ready by the end of this year. We believe that active immunization may offer advantages over passive anti-TNFa monoclonal antibody therapy, by potentially limiting therapeutic failure related to the formation of anti-idiotypic antibodies. Moreover, the potential low frequency of boost immunizations would increase patient compliance."

TNFa is a well-established pro-inflammatory mediator. In hTNFa expressing transgenic mice (TTg mice), a mouse model of rheumatoid arthritis, animals receiving the Debio-0512 therapeutic vaccine developed high levels of anti-TNFa antibodies, neutralising both TNFa bioactivity and binding of TNFa to its receptor. This study shows that immunization with Debio-0512 effectively controls pathogenic effec
'"/>




Page: 1 2

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... --   Masimo (NASDAQ: MASI ... Acoustic Monitoring™, and Masimo SET ® Measure-Through Motion ... Medical Devices, Inc. dismissed all outstanding claims against Masimo ... and Cercacor.   Masimo did not incur any liability to ...
... QBC Diagnostics, a global manufacturer of hematology ... the company has been awarded a U.S. General ... Equipment and Services. GSA,s Scientific Equipment ... with scientific instruments for a wide variety of ...
Cached Medicine Technology:Essential Medical Dismisses Patent Case against Masimo and Cercacor 2Essential Medical Dismisses Patent Case against Masimo and Cercacor 3Essential Medical Dismisses Patent Case against Masimo and Cercacor 4QBC Diagnostics Awarded GSA Contract 2
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... national provider of tele-health solutions, has received full accreditation from URAC ... URAC assures that SironaHealth has met all relevant standards and performs ... is timely, confidential, and includes medically appropriate care and treatment advice. ... ...
... complete medical travel packages for North American patients seeking ... ... Long Beach, Calif. (PRWEB) April 8, 2009 -- With U.S. ... trillion this year, health insurers, self-insured employers, groups and individuals are ...
... Multiple, anatomically distinct lung cancer tumors may frequently arise ... analysis of patient tumor samples published in the April ... National Cancer Institute. , Some lung cancer patients ... diagnosis. Although such multiple tumors usually share a common ...
... that the growth factor known as TGF-β is essential to ... blocking it can cause retinal dysfunction. These findings, published in ... have an important impact on the prevention and treatment of ... results are significant because they add to our understanding of ...
... testing after ,very promising, early results, , , TUESDAY, April ... radically different way of attacking prostate cancer has done ... larger-scale testing, researchers report. , One standard treatment for ... male hormones such as testosterone that help drive tumor ...
... women, not men, researchers report , , TUESDAY, April 7 ... the list of cardiac problems linked to overweight and ... however we measure it, is associated with the risk ... fellow at the Cardiovascular Epidemiology Research Unit of Beth ...
Cached Medicine News:Health News:SironaHealth Receives URAC Accreditation as a Health Call Center 2Health News:SironaHealth Receives URAC Accreditation as a Health Call Center 3Health News:Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers 2Health News:Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers 3Health News:Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers 4Health News:Multifocal lung cancers appear to originate from single cancer clone 2Health News:Growth factor TGF-B helps maintain health of retinal blood vessels 2Health News:New Prostate Cancer Drug May Hold Promise 2Health News:New Prostate Cancer Drug May Hold Promise 3Health News:Obesity Linked to Heart Failure Risk 2
... unique DHEA-S-7kits feature a ... against the C-7 position ... with no cross-reactivity with ... RIA has been optimized ...
... based on the competition principle and the ... present in the sample and a fixed ... compete for the binding sites of a ... After one hour incubation the microtiterplate is ...
Inquire...
... It is a compact Latex based reagent kit ... well as to determine the level of RF ... patient sera. The kit includes antigen coated fine ... control sera in plastic squeezable dropping bottles, re-usable ...
Medicine Products: